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Abstract
Background: Outer membrane vesicles (OMVs) are constitutively produced by Gram-negative bacteria throughout
growth and have proposed roles in virulence, inflammation, and the response to envelope stress. Here we
investigate outer membrane vesiculation as a bacterial mechanism for immediate short-term protection against
outer membrane acting stressors. Antimicrobial peptides as well as bacteriophage were used to examine the
effectiveness of OMV protection.
Results: We found that a hyper-vesiculating mutant of Escherichia coli survived treatment by antimicrobial peptides
(AMPs) polymyxin B and colistin better than the wild-type. Supplementation of E. coli cultures with purified outer
membrane vesicles provided substantial protection against AMPs, and AMPs significantly induced vesiculation. Vesicle-
mediated protection and induction of vesiculation were also observed for a human pathogen, enterotoxigenic E. coli
(ETEC), challenged with polymyxin B. When ETEC with was incubated with low concentrations of vesicles concomitant
with polymyxin B treatment, bacterial survival increased immediately, and the culture gained resistance to polymyxin B.
By contrast, high levels of vesicles also provided immediate protection but prevented acquisition of resistance.
Co-incubation of T4 bacteriophage and OMVs showed fast, irreversible binding. The efficiency of T4 infection was
significantly reduced by the formation of complexes with the OMVs.
Conclusions: These data reveal a role for OMVs in contributing to innate bacterial defense by adsorption of
antimicrobial peptides and bacteriophage. Given the increase in vesiculation in response to the antimicrobial peptides,
and loss in efficiency of infection with the T4-OMV complex, we conclude that OMV production may be an important
factor in neutralizing environmental agents that target the outer membrane of Gram-negative bacteria.
Background
Bacteria, especially pathogenic bacteria, must deal with a
very hostile environment on a nearly continuous basis.
How pathogenic bacteria first respond to this environ-
ment and lethal environmental stressors is a key element
in their survival. Based on their initial response, either
the pathogen may succumb and die, or it can respond
and live despite its hostile surroundings. Long-term
adaptive bacterial responses to antimicrobials include
well-characterized mechanisms of expressing an altered
version of the antibiotic target, enzymes to degrade the
antibiotic, and transporters to remove the antibiotic [1].
Here, we consider the time immediately after the first
exposure to a threat and before activation of long-term
adaptive resistance to stressors. Understanding how
bacteria mount this initial defense against stresses is criti-
cal to understanding how bacteria respond to, and sur-
vive, hostile environments.
We propose that bacterial outer membrane vesicles
(OMVs) and OMV production may play a key role in
innate bacterial defense against environmental stressors
that target the cell envelope, as well as sub-inhibitory con-
centrations of outer membrane targeting antibiotics.
OMVs are spherical portions of bacterial envelope contain-
ing outer membrane protein and lipid as well as soluble
material contained in the lumen or bound to the external
surface [2,3]. The role of OMVs in intercellular transport
and signaling by pathogenic bacteria has been the subject
of numerous studies [3]. However, only a few reports
investigated more generally beneficial roles for OMVs that
would explain their development in non-pathogenic Gram-
negative bacterial species. Of these, some have described a
role for OMVs in countering environmental stress and
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stressors. For instance, one report demonstrated that
OMVs are induced by and protect bacteria from toluene
exposure [4], and others reported that OMVs contribute to
the formation of biofilms which have a well-known role in
bacterial resistance to harsh environments [5,6]. In addi-
tion, Grenier et al discovered that OMVs from Porphyro-
monas gingivalis could protect cells against chlorhexidine,
as well as provide degradative enzymatic activities to neu-
tralize the killing abilities of human serum [7,8]. Further-
more, mutations resulting in hyper-production of OMVs
were found to be advantageous when E. coli was challenged
with otherwise lethal environmental stresses, including
antimicrobials and ethanol, a general denaturant [4,9].
Natural antibiotics are common antimicrobial stressors
encountered by bacteria in the environment as well as
during infection of a host. Antimicrobial peptides (AMPs)
are a key human defense to bacterial infections, as well as
a defense employed by other Gram-positive and Gram-
negative bacteria [10,11]. Antimicrobial peptides have also
been found in a growing variety of other host organisms,
including mice, insects, and frogs [12-15]. Few, however,
acknowledge the sub-inhibitory concentrations of these
defensins that pathogens commonly encounter on the
epithelial surfaces, or in the environment [10,16]. The
most common mechanism of action for these AMPs is
alteration of bacterial membrane permeability, typically by
pore formation [15,17,18]. Because of their generic target
and their speed of action, AMPs have recently been revis-
ited in the quest to develop novel antibiotics against
Gram-positive and Gram-negative pathogens [14,19-22].
Currently, AMPs are used as a last line of defense against
some multi-drug resistant pathogens [22-24]. Most bacter-
ial AMP-resistance is characterized by lipid modifications
to alter the charge of the outer membrane [25-27]. How-
ever these resistance pathways cannot fully explain the
extent of resistance seen in Gram-negative bacteria [16].
We hypothesize that OMVs may act as a modulating
intrinsic defense against AMPs as well as other outer
membrane acting stressors, and that this defense may help
to explain the gap in our current understanding of how
Gram-negative bacteria respond to these compounds.
Phage are ubiquitous viral particles found in all niches of
life, and at an estimated 1031 phage on the earth, they are
the most prevalent organisms on the planet [28,29]. A
majority of these viral particles are considered to be bac-
teriophage, phage that specifically infect bacteria [28].
With the advent of metagenomics and the drive to study
the microbiomes of not only environmental niches but
also human niches, more and more bacteriophage are
being discovered [30]. The addition of another player in
the bacterial-host interaction matrix increases the com-
plexity of the environment beyond what is currently
appreciated, presenting yet another set of interactions to
consider. Bacteriophage are specific to the host they
replicate within [29]. Phage that infect Gram-negative bac-
teria typically identify their host by binding the outer
membrane or one of its components [28]. As OMVs con-
sist of components of the Gram-negative outer membrane,
it seems logical that these blebs may play an important
role in the interaction between bacteria and phage. Early
work done by Loeb et al has already demonstrated a dra-
matic increase in outer membrane production and release
in the presence of T4 phage in E. coli [31]. This study
aims to characterize the interaction between OMV and T4
phage and determine its effect on the efficiency of phage
infection.
In this work, we investigate the ability of OMVs to
adsorb diverse outer membrane antimicrobial agents
(AMPs and bacteriophage T4), and we determine if
OMVs can contribute to the protection of Gram-negative
bacteria against these lethal stressors. We examine if
OMVs are induced in the presence of AMPs and investi-
gate whether OMV-mediated protection and induction
properties hold true for the human pathogen, enterotoxi-
genic E. coli (ETEC). We also investigate whether the pre-
sence of OMVs affect the ability of ETEC to express long-
term, adaptive resistance to polymyxin B and the ability of
E. coli to protect against phage over several replication
cycles. Overall, our data support a model of intrinsic bac-
terial defense based on OMVs. This work supports the
hypothesis that in certain environmental conditions,
Gram-negative bacteria can use vesiculation as an immedi-
ate protective response.
Results
Increased survival by a hyper-vesiculating mutant after
antimicrobial peptide stress
We first examined whether mutations that result in hyper-
vesiculation protect bacteria against antimicrobial chal-
lenge. A wild-type (WT) laboratory E. coli and the isogenic
hyper-vesiculating yieM mutant (ΔyieM) were selected for
these studies. Compared to WT, a mutant harboring a
transposon disruption of yieM hyper-vesiculates approxi-
mately 10-fold yet displays WT membrane integrity [9].
The full yieM knockout, ΔyieM, maintains all of the phe-
notypes previously described for the transposon mutant.
Polymyxin B and colistin are cyclic cationic antimicro-
bial peptides (AMPs) that act at the outer leaflet of the
outer membrane, forming pores and altering membrane
permeability [16,17,32]. Log-phase cultures of the strains
were treated with the AMPs at a range of antibiotic con-
centrations just below the dose conferring ~10% survival
of WT cultures. Cultures of the ΔyieM grew significantly
better than WT in polymyxin B and colistin over a range
of treatment doses (Figure 1A, B). Since the deletion of
yieM does not cause a change in the lipid A structure of
the LPS (Additional File 1, Figure S1B, C), these data sug-
gest that hyper-vesiculation is protective against these
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AMPs. When treated with antibiotics that target peptido-
glycan synthesis and protein synthesis (ceftriaxone, ampi-
cillin, and tetracycline), the mutant demonstrated
minimal or no change in growth phenotypes compared
to the WT (data not shown). Together, these results sug-
gest that vesicles can serve a protective function for some
antibiotics, notably those antibiotics that interact signifi-
cantly with the outer membrane.
Outer membrane vesicles mediate protection against
antimicrobial peptides
Secreted OMVs might help to defend cells against outer
membrane-acting antibiotics based on the nearly identical
surface constituents of the OMVs and the bacterial outer
membrane. To address this possibility, we tested directly
whether addition of purified OMVs could increase the sur-
vival of WT bacteria challenged with antibiotic. WT cul-
tures were treated with antibiotic in the presence or
absence of purified OMVs and growth was measured. The
time course of the experiment was kept brief so the
amount of OMVs the strain itself produced during the
trial would be negligible compared with the quantity of
OMVs added. A high OMV concentration was used in
these initial experiments in order to detect whether there
would be any effect. The simultaneous addition of OMVs
with the polymyxin B or colistin treatment resulted in sig-
nificantly increased survival compared to cultures treated
with those antibiotics alone (Figure 1C). OMVs were not
Figure 1 OMV-mediated protection to AMPs. Relative survival of WT (solid line) and ΔyieM (dashed line) E.coli after 2 h treatment with the
indicated concentrations of polymyxin B (A) and colistin (B). (C) Cultures of mid-log phase WT E. coli were simultaneously treated with the
indicated antibiotic (polymyxin B (PMB) 1.5 μg/mL and colistin (COL) 1.0 μg/mL) and either no OMVs (black bars) or with OMVs purified from WT
E.coli (4 μg/mL) (grey bars). (D) To titrate OMV-mediated protection, indicated concentrations of WT OMVs were co-incubated in media for 2 h
with indicated concentrations of polymyxin B and the media cleared of OMVs by centrifugation. Polymyxin B activity remaining in the media
was assessed by adding the pretreated media to a mid log-phase culture of WT E. coli, incubating for 2 h, and plating for CFU. Relative growth
(% Survival) was determined by dividing the CFU/mL obtained from antibiotic-treated cultures by the CFU/mL from cultures without antibiotic.
(n = 9 for all experiments).
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effective in protecting against ampicillin, ceftriaxone, or
tetracycline, and OMVs alone had no effect on growth of
untreated cultures (data not shown and Additional File 2,
Figure S2).
To determine the extent by which OMVs could titrate
AMP activity in the media, we incubated media containing
a range of polymyxin B concentrations (0 to 20 μg/mL)
with a range of OMV concentrations (0 to 4 μg/mL). The
OMVs were removed via centrifugation and the poly-
myxin B activity remaining in the pre-incubated media
was assessed indirectly. WT log-phase E. coli was treated
with the pre-incubated media and bacteria survival was
quantitated. We observed a depletion of polymyxin B
activity in the media that depended on the concentration
of OMVs (Figure 1D). The minimum ratio of OMVs to
polymyxin B in the pre-incubation that resulted in com-
plete protection was 4 μg OMV to 7 μg polymyxin B in
1 mL of culture. These data demonstrate that full mitiga-
tion of the bactericidal effects of polymyxin B could be
achieved by the OMVs.
Antimicrobial peptide treatment induces vesicle
production
As protection was dependent on OMV concentration, we
considered whether WT bacteria could be induced by anti-
biotic treatment to produce increased amounts of OMVs.
For these experiments, it was particularly important to
thoroughly control for the possibility that the antibiotic
treatments would lyse cells, since this would obscure quan-
titation of OMVs. Therefore, we examined bacterial integ-
rity for cultures treated with the maximum concentration
of antibiotic that resulted in the lowest amount of killing
(0.75 μg/mL polymyxin B, ≥ 95% survival; colistin 0.5 μg/
mL). To test for the loss of cell wall integrity, the presence
in culture supernatants of the constitutively-expressed peri-
plasmic enzyme alkaline phosphatase (AP) was monitored.
We prepared cell- and OMV-free supernatants from trea-
ted and untreated cultures and measured AP activity in the
supernatants and corresponding cell pellets. The ratio of
AP in the OMV-free supernatant for the treatments used
for subsequent vesiculation induction assays was not signif-
icantly affected by the treatments (Table 1). We also exam-
ined the morphology of polymyxin B-treated cells by
electron microscopy and found that the treated cells and
the OMVs prepared from the induced cultures did not
appear ruptured or morphologically different from
untreated samples (data not shown). Furthermore, OMV
and subcellular fractionation protein profiles for both trea-
ted and untreated cultures of E. coli were nearly identical
(Figure 2A, Additional File 3, Fig S3). Together, this set of
control experiments demonstrated that the antibiotic treat-
ments did not affect cell integrity and that measurements
of induced OMVs in treated cultures were not inaccurate
due to products of cell lysis.
To investigate whether vesiculation was induced upon
treatment, we used a previously designed quantitative
assay to measure OMVs in the culture supernatant [9].
Whereas other antibiotic (tetracycline, ampicillin, and cef-
triaxone) treatments each modestly increased vesiculation
(2 to 4 fold, data not shown), polymyxin B and colistin
each increased OMV production substantially (10-fold)
(Figure 2B). Therefore, the greatest induction of vesicula-
tion occurred in response to the same antibiotics, poly-
myxin B and colistin, for which OMVs mediate protection.
Protection and induction of OMVs produced by
pathogenic E. coli
We studied a clinical isolate of enterotoxigenic strain of
E. coli (ETEC) to evaluate whether OMV-mediated pro-
tection and stress-induced OMV production also occurs
for a pathogenic strain of E. coli. Although this ETEC
strain is intrinsically more resistant to polymyxin than
K12 E. coli, the addition of either purified K12 OMVs or
ETEC OMVs to ETEC cultures further protected the
bacteria from killing by polymyxin B (Figure 3A). By
titrating in purified ETEC OMVs, we observed that the
survival of a mid-log phase culture of ETEC treated with
4 μg/mL polymyxin significantly increased from 0% to
nearly 50% with the addition of 3-4 μg/mL ETEC OMVs
(Figure 3B).
In addition, although ETEC already produces a higher
basal level of OMVs than K12 strains, ETEC OMV pro-
duction was significantly induced after polymyxin B treat-
ment (nearly 7-fold) as compared to untreated cultures
(Figure 3C). Control experiments confirmed that the treat-
ment did not cause significant cell lysis (< 5% reduction of
CFU and no significant change in periplasmic AP in the
OMV-free culture supernatant, Table 1). Thus, upon
AMP challenge, both K12 and pathogenic E. coli strains
are induced to produce protective OMVs.
OMV-mediated protection and induction of OMVs depend
on the antibiotic sensitivity of the strain
We next considered the likelihood that OMVs adsorb
polymyxin B by the interaction between OMV lipopoly-
saccharide (LPS) and the antibiotic. Based on the fact
that polymyxin resistant strains produce modified LPS
that cannot bind polymyxin B [27,33], we predicted that
OMVs produced by a resistant strain would not interact
with polymyxin B and, consequently, would not confer
protection to a sensitive strain. To test this, we derived a
polymyxin-resistant strain of ETEC (ETEC-R) by treating
mid-log phase ETEC cultures with a high concentration
of polymyxin B. LPS isolated from ETEC-R was analyzed
by mass spectroscopy and was confirmed as having a
modified lipid A consistent with a phosphoethanolamine
attached to the phosphate in the 1 position (Additional
File 1, Figure S1E). This is consistent with previously
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seen lipid A modifications that alter the charge of the
outer membrane [34].
OMVs purified from ETEC-R (R-OMVs) were simulta-
neously added with polymyxin B to a non-resistant ETEC
culture. The ETEC-R-OMVs offered no protection at a
concentration where ETEC-OMVs were previously seen
to be maximally protective (Figure 3A). These data
demonstrated that polymyxin B adsorption by the LPS of
the OMV is the likely mechanistic basis for OMV-
mediated resistance.
Interestingly, when we investigated polymyxin-induced
vesiculation for ETEC-R, we found that vesicle produc-
tion by ETEC-R did not significantly increase upon
treatment with 10 μg/mL polymyxin B (Figure 3D).
Therefore, it appeared that the mechanism by which
OMV production is induced depends on polymyxin
interaction with cellular LPS.
OMVs alter antibiotic resistance phenotype in ETEC
Adaptive (longer-term) bacterial resistance to polymyxin is
typically based on the upregulation of genes which lead to
the modification of LPS [27,33]. We wondered whether
OMV-mediated defense would affect the onset of adaptive
resistance of ETEC to polymyxin B. A mid-log liquid cul-
ture of ETEC was treated with polymyxin B (3.5 μg/mL)
and concurrently supplemented with either a relatively
high concentration of ETEC OMVs (2 μg/mL) or buffer.
Samples were taken hourly for up to 7 h post treatment,
spread on LB agar and LB agar containing polymyxin B,
and the plates inspected after 12 h incubation at 37°C








Strain Treatmentb UNT TRE UNT TRE Untreated Treated
MK318 Polymyxin B
(0.75 μg/mL)
8.270 ± 1.010 7.870 ± 0.970 1.290 ± 0.080 1.341 ± 0.121 0.160 ± 0.007 0.170 ± 0.006
Colistin
(0.5 μg/mL)
9.440 ± 0.230 8.87 ± 0.07 1.20 ± 0.010 1.260 ± 0.021 0.127 ± 0.003 0.121 ± 0.002
ETEC Polymyxin B
(3 μg/mL)
6.100 ± 0.440 6.07 ± 0.510 1.201 ± 0.030 1.22 ± 0.030 0.198 ± 0.009 0.204 ± 0.020
ADA600 Untreated 0.020 ± 0.011 ND 0.024 ± 0.013 ND ND ND
aRFU measurements of AP in the OMV-free culture supernatant (Supe) compared to AP in whole cell (WC) pellets, normalized to CFU/mL in the culture. No
significant differences in AP leakage between untreated (UNT) and treated (TRE) cultures were observed (p > 0.05).
bTreatments were for 2 h at 37°C; final concentration of treatments are shown. (n = 9)
Figure 2 OMV production is substantially induced by AMPs. (A) OMVs from 0.75 μg/mL polymyxin B-treated (+) and untreated (-) WT
cultures were purified, separated by SDS-PAGE, and stained using SYPRO Ruby Red. OMVs from strain ΔyieM are also shown for comparison. No
significant differences in protein content could be identified across all samples. Molecular weight standards are indicated in kDa (M). (B) OMVs in
the cell-free culture supernatant of antibiotic-treated WT cultures (0.75 μg/mL polymyxin B, PMB; or 0.5 μg/mL colistin, COL) were quantitated by
measuring outer membrane protein and compared with the quantity of OMVs produced by untreated cultures (Untreated). Production was
normalized to CFU/mL of each culture at the time of OMV preparation, and relative fold-differences are shown. (n = 9 for all experiments).
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(Figure 4). As expected from the results described earlier,
ETEC cultures supplemented with OMVs survived better
compared to cultures that did not contain added OMVs
(Figure 4B, C). However, we further observed that these
bacteria were not able to grow on plates containing poly-
myxin B (Figure 4D). This suggests that the bacteria sur-
vived to a greater extent but did not become adapted to
resist polymyxin.
To test if the bacteria in the OMV-supplemented cul-
ture were simply incapable of becoming adaptively resis-
tant, an additional 5 μg/ml polymyxin B was added at
hour 5 after the OMV-polymyxin B co-incubation and the
culture was then plated on polymyxin B-containing agar.
Resistant ETEC were observed without a detectable
decrease in cell number after 7 h (Figure 4E). This result
demonstrated that the OMV-protected ETEC had the
capacity to adapt to high levels of antibiotic and achieve
resistance if the polymyxin dose was increased beyond the
amount the OMVs could protect. This reasoning was con-
firmed in further experiments in which we used a lower
OMV concentration (0.7 μg/ml) with the same concentra-
tion of polymyxin B. In these cultures, particularly at 1-4 h
time points, fewer ETEC survived than for cultures where
the higher OMV dose was added (Figure 4B, G), but the
surviving bacteria more quickly adapted to polymyxin B,
as demonstrated by their ability to grow on polymyxin B-
containing agar (Figure 4I). When comparing the growth
of supplemented and un-supplemented cultures, we con-
clude that low doses of OMVs promoted ETEC growth in
polymyxin B at least 3 h earlier than with no added OMVs
at all (Figure 4G, H). Thus, at low concentrations, OMVs
confer immediate maintenance of bacterial viability and
do not impede the activation of adaptive resistance. At
higher concentrations, OMVs confer immediate resistance
Figure 3 ETEC, not ETEC-R, OMVs are protective and induced by polymyxin B. (A) A mid-log culture of ETEC was treated with polymyxin B
(4 μg/mL, final concentration) simultaneous with no addition (PMB), 10 μg of WT (K12) OMVs (PMB + OMV), 10 μg of ETEC-derived OMVs (PMB +
ETEC OMV), or 10 μg ETEC-R-derived OMVs (PMB + R-ETEC-OMV). Relative growth (% Survival) was determined compared to cultures without
antibiotic (Untreated). (n = 9) (B) To titrate OMV-mediated protection for ETEC, ETEC OMVs (final concentrations indicated) were added
simultaneously with polymyxin B (5 μg/mL, final concentration) to a mid-log phase ETEC culture and co-incubated 2 h at 37°C. Relative growth
(% Survival) was determined compared to cultures without antibiotic. (n = 6) OMV yield was quantitated for mid-log phase cultures of ETEC (C)
or ETEC-R (D) treated for 14 h with 3 μg/ml polymyxin B. (n = 6 for both C and D) OMV production was normalized to the CFU/mL of each
culture at the time of vesicle harvest, and relative fold-differences compared to untreated cultures are shown.
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of the bacterial population but adversely affect bacterial
acquisition of adaptive resistance.
T4 Bacteriophage interact with OMVs and OMVs decrease
efficiency of infection
To further test the hypothesis that OMVs can help in
defense against outer membrane-acting stressors, we
investigated whether OMVs could protect E. coli from
infection by bacteriophage T4. Co-incubation of T4 and
OMVs resulted in a dramatic reduction of active phage
(by approximately 90%), as measured by a reduction in
plaque forming units (PFUs) (Figure 5A). To characterize
the putative interaction between the phage and OMV we
used the differential chloroform resistance properties of
free or reversibly-bound phage, and irreversibly-bound
phage. Chloroform is commonly used in the preparations
of T4-phage lysates, since it acts to physically disrupt the
membrane of living bacteria to free the replicated phage
from cells, as well as to kill the bacteria and stop phage
production [35]. Reversibly-bound phage are chloroform
resistant and will remain infective following treatment,
whereas irreversibly-bound phage are unable to cause
infection following chloroform treatment. Immediately
after mixing T4 and OMVs, and at 5 min intervals there-
after, the mixtures were treated with chloroform to break
apart the OMVs. Following a 30 min shaking incubation
at 37°C, the preparations were titered (Figure 5B). We
found that inactivation of T4 by the addition of OMVs
occurred very quickly. At the initial time point, we
already observed a 60% reduction in infectious phage. By
5 min, we saw an 80% reduction in the free phage, and by
one hour, we saw further reduction, until only approxi-
mately 10% of the original phage activity remained. Based
on the time-course of the reduction in the numbers of
active T4 in the chloroform-treated OMV-phage mixture,
we concluded that T4 are binding to the OMVs in a fast
and irreversible manner.
In order to reveal the longer-term effects of the presence
of OMVs on T4 infectivity in a microenvironment, we
observed the infection and reproduction of the phage in
the mixture following a 1 h incubation with the titer
strain. After we co-incubated the T4 and OMVs, we
added this mixture to growing cultures of the titer strain
and incubated for 1 hour instead of only 5 min. This time-
point is sufficient to allow several cycles of infection and
allowed us to observe whether the OMVs in the mixture
Figure 4 Acquisition of ETEC resistance to polymyxin B is reduced by co-incubation with high concentrations of OMVs. At hourly time-
points for 0-7 h of co-incubation, equivalent volumes of the samples described below were streaked on each plate in a pattern indicated by the
template diagram. Top row: ETEC co-incubated with (A) nothing, (B, D) a high concentration of ETEC OMV (2 μg/mL) and polymyxin B (3.5 μg/
ml), or (C) polymyxin B alone (3.5 μg/mL). Samples were streaked either on LB agar (A-C), or LB containing 5 μg/ml polymyxin B (D-E). (E) ETEC
co-incubated with ETEC OMV (3 μg/mL) and polymyxin B (3.5 μg/mL) for 5 h, then an additional 5 μg/mL polymyxin B was added, and plated
on LB containing 5 μg/mL polymyxin B. Resistance was seen by hour 7 without decreasing cell population significantly. Bottom row: ETEC co-
incubated with (F) nothing, or (G, I) 1.4 μg/mL ETEC OMV and 3.5 μg/ml polymyxin B, and (H, J) polymyxin B alone (3.5 μg/mL), streaked on LB
(F-H) or LB containing 5 μg/mL polymyxin B (I-J). (n = 9 for all experiments).
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have an affect beyond the initial inactivation. To use as a
comparison, we first determined the amount of free phage
(105) that produced the equivalent PFUs to the amount of
infectious phage in the mixture when it was incubated
with the titer strain for only 5 min (Figure 5A, 5 min).
Then we compared the amount of PFUs formed after a 60
min incubation of cells incubated with 105 T4 or with the
mixture of T4 and OMVs. We found that the sample con-
taining the mixture of T4 and OMVs contained fewer
infectious phage as compared to both the original 106 T4
as well as the 105 free T4 samples (Figure 5A, 60 min).
This suggests that the addition of OMVs to T4 signifi-
cantly reduces the infectivity of T4 over several genera-
tions of phage infection.
Figure 5 T4 phage bind OMVs, reducing their capacity to infect E. coli. (A) 106 T4 phage were co-incubated with 1 μg purified WT OMVs
(106 T4+OMV) for 2 h. As controls, 106 T4, 1 μg of purified WT OMVs, and 105 T4 were also incubated under the same conditions for 2 h. For
the 5 min panel, samples were mixed with MK496 cells and allowed to incubate for 5 min, PFU were then determined and compared to the
PFU produced by the 106 T4 sample (% PFU Remaining). For the 60 min panel, the phage and WT OMV preparations were incubated for 1 h
with mid log-phase MK496 cells, PFU were determined, and compared to the PFU produced by the 106 T4 sample (% PFU Remaining). (n = 9)
(B) 106 T4 phage were mixed with 1 μg purified WT OMVs, then immediately ("0” min), and at 5 min intervals thereafter, samples were taken
and chloroform was added to disrupt the OMVs and allow reversibly bound phage to be released. The T4 activity in each sample was
determined by PFU titration and compared to the PFU produced by 106 T4 (% PFU Remaining). (n = 6) (C) Negative stain electron micrograph
of the T4-OMV complex (size bar = 50 nm).
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Finally, we used electron microscopy to determine
whether complexes between T4 and OMVs could be
visualized. We found many complexes between T4 and
OMV (an example is shown in Figure 5C), and in these
cases, T4 was in a similar orientation as was observed
between T4 and bacterial cell wall [36]. These data sup-
port the model that released OMVs and vesiculation
may contribute to the innate bacterial defense against
outer-membrane acting stressors.
Discussion
Understanding how bacteria manage to survive in hostile
environments has been an important step towards under-
standing bacterial defense and pathogenesis. As our
understanding of the bacterial world has increased, so
has our appreciation of the complexity of the constant
interactions that occur between bacteria and their envir-
onment. These include the well-studied interactions that
occur between a pathogen and the host environment, as
well as the less-appreciated interactions that occur
between bacteria and the general environment. With the
current escalation in the variety of antimicrobial resistant
bacteria, a particularly critical topic concerning bacterial-
environment interactions is the bacterial response to the
presence of an antibiotic. Many reports discuss the differ-
ent pathways that allow microbes to adapt to antibiotics
and achieve antimicrobial resistance (drug export, target
modification, etc.) [1,37-40], but how bacteria survive the
initial antibiotic assault is less well understood. Addition-
ally, it is not well understood how bacteria respond to
challenge with sub-lethal concentrations of antibiotics.
These concentrations are relevant to this study because
they are likely to be encountered clinically, by bacteria
within biofilm communities (where therapeutic concen-
trations of antibiotics cannot easily penetrate and high
OMV concentrations exist [6]) and during improper anti-
biotic dosing regimens, as well as in antibiotic-contami-
nated niches in the general environment.
In this study we show that OMVs represent an exported
form of an inducible innate defense to sub-lethal concen-
trations of AMPs for both non-pathogenic and pathogenic
E. coli. The concept that OMVs enable antibiotic resis-
tance has been presented for b-lactam drugs in several stu-
dies demonstrating OMVs can carry active b-lactamase
[41,42]. However, the idea that OMVs themselves can
confer protection, without the need for an enzymatic resis-
tance, has been less well studied, with only one report
demonstrating that chlorhexadine can be adsorbed by
OMVs in P. gingivalis [8]. The protection we observe is
specific for outer membrane-targeting stressors, and we
show that vesiculation is highly induced upon treatment
with AMPs for which the OMVs are protective. Further-
more, as OMV protection can affect not only immediate
survival, but also the acquisition of adaptive antibiotic
resistance in a dose-dependent manner, it is important to
consider the role of vesiculation as a short-term, low dose,
antimicrobial defense mechanism that can affect long-
term survival.
We observed that OMV-mediated defense against anti-
microbials was limited to compounds that act at the outer
membrane (AMPs). An association between OMVs and
antibiotics was previously reported in a study demonstrat-
ing the trafficking of gentamicin within P. aeruginosa
OMVs, and in this case is was presumed that the gentami-
cin reached the lumen of the OMV [43]. In the case of
either polymyxin B or colistin interactions, OMVs likely
confer protection via an adsorption mechanism. There
have been no enzymatic mechanisms of resistance discov-
ered to date [17,44], and thus it is highly unlikely that the
OMVs convey enzymatic protection. Interactions between
outer membrane LPS and AMPs have already been well
documented [16], and our results further support this
mechanism. Purified OMVs provided dose-dependent pro-
tection for polymyxin-treated cultures (Figure 1D, 3B), and
the type of OMV LPS was paramount to OMV-mediated
polymyxin protection, as OMVs from the polymyxin-resis-
tant ETEC strain were not protective (Figure 3A). This
suggests that OMVs present binding sites, acting as cellu-
lar decoys, for outer membrane-targeting stressors.
Whether bacteria can produce a protective concentration
of OMVs in a physiological environment is a valid consid-
eration. We propose that AMP-protective concentrations
of OMVs are likely to be achieved in relevant settings for
several reasons. First, a 10-fold increase in OMV concentra-
tion was sufficient for a K12 E. coli strain to gain significant
protection (e.g. for the yieM mutant, Figure 1A, B). There-
fore, the basal level of OMV production by untreated
ETEC (which is approximately 10-fold higher than lab
strains of E. coli [45]), is already sufficiently high to provide
some intrinsic OMV-based AMP defense. Pathogenic
strains generally make constitutively more OMVs than
laboratory strains [45], so this likely holds for other species
as well. Second, AMP treatment induced OMV production
another 7-fold beyond the already high basal level for
ETEC. Indeed, the high basal level coupled with induced
OMV production could help explain the previously noted
high intrinsic resistance of ETEC to polymyxin B and colis-
tin [22]. Finally, in a natural setting, such as a colonized
host tissue or biofilm, there is a gradient of antibiotic con-
centration [46,47] as well as high concentrations of OMVs
[6]. Together, the induction of already high basal levels of
OMV production and the concentration by the host micro-
environments would be sufficient to yield short-term,
OMV-mediated AMP protection.
We did note the incomplete (albeit 50%) protection of
ETEC by the purified OMVs (Figure 3A, B). If enough
OMVs were used, it is possible that we could have achieved
100% protection, however, we felt that concentrations
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exceeding those used in this study would be unreasonable.
It should be further emphasized that the goal of an immedi-
ate, innate bacterial defense mechanism is to quickly impart
an advantage, not necessarily to achieve 100% protection. In
addition, OMV-dependent modulation of the adaptive
response to polymyxin B (Figure 4) suggests that there is
likely an optimal level of OMV induction in response to
AMPs. The optimal amount would be sufficient to achieve
immediate protection, and maintain a viable population,
while being low enough to allow bacteria exposure to the
AMPs so that adaptive resistance would still be stimulated
in that population.
The observation that AMPs specifically induced vesicu-
lation suggests that OMV formation is a regulated
response by the bacteria. The induction pathway depends
at least partially on the ability of the AMP to bind LPS
since the polymyxin did not induce vesiculation in the
ETEC-R strain (Figure 3D). Recently, Fernandez et al dis-
covered a sensor system in Pseudomonas aeruginosa that
is distinct from the PhoP-PhoQ or PmrA-PmrB two
component systems and that is responsible for sensing
the polymyxin B peptide in more physiological conditions
[48]. This system, composed of ParR-ParS, is tied to acti-
vation of the arnBCADTEF LPS modification system
[48]. The existence of the ParR-ParS system suggests that
there could be a similar sensor that responds to binding
of AMPs to LPS and modulates OMV production. We
propose that such a response to AMPs is what could lead
to physiologically protective levels of OMVs.
To extend our investigation of ubiquitous stressors
found in both host and natural environments that attack
via the outer membrane, we chose to investigate T4 bac-
teriophage [16,28]. T4 is a well-studied bacteriophage and
is already linked to overproduction and release of outer
membrane [31]. Our results show that there is significant
binding and reduction of infection when T4 was pre-incu-
bated with OMVs (Figure 5). In order to investigate the
binding interaction between T4 and OMVs, we took
advantage of the resistance of T4 to chloroform treatment.
Chloroform disrupts the bacterial outer membrane and
results in the release of active T4 only if the binding is
reversible. T4 phage undergoes two general steps in bind-
ing prior to injection of its genetic material, the first is a
reversible step where long tail fibers bind the LPS of the
outer membrane of the host, the second is an irreversible
step whereby the short tail fibers identify and bind to a
cognate host factor [49]. Once this second step occurs,
chloroform treatment will not free the phage to allow
them to infect and replicate (visualized by the formation
of plaques on a lawn of plated E. coli). Upon addition of
OMVs, we clearly observed an immediate reduction in the
population of infectious phage (Figure 5B), demonstrating
that T4 binding to OMVs is quick and irreversible.
Although we tried to amplify phage DNA from T4-OMV
complexes, we could not definitively determine if the
bound phage had injected its DNA into the OMV (data
not shown).
When we compared the infectivity of T4 in a mixture
with OMVs and that of 105 T4 using conditions that
allow several cycles of infection, we found that over the
long-term, infectivity of T4 in the OMV mixture was
reduced (Figure 5A, 60 min panel). This experiment
highlights the ability of OMVs to continue binding and
inactivating T4 beyond the initial binding event and
thereby greatly impact the rate of bacterial infection by
phage in the environment.
Our results suggest a model in which vesiculation is an
inducible “innate immune” mechanism for bacterial
defense. In this model, a community of bacteria encoun-
ters an outer membrane-acting stressor. When the stres-
sor is encountered, some bacteria will die, while
vesiculation is induced for others. This is beneficial for
several reasons: the stressor is shed, relieving the cell of
the stress, and also the local and global concentration of
OMVs significantly increases, benefiting itself as well as
neighboring cells by their ability to neutralize cell sur-
face-acting stressors. The period of hyper-vesiculation
also can offer an opportunity for a greater number of
cells to modify their outer membrane and generate resis-
tance, such as altering their LPS structure so that it
resists binding to AMPs [27,33]. Therefore, while OMVs
are a short-term defense against low-doses of cell wall
stressors, vesiculation can also contribute to long-term
protective mechanisms that Gram-negative bacteria use
to extend life in hostile environments.
Conclusions
OMVs can adsorb outer membrane-acting compounds
including antimicrobial peptides and T4 bacteriophage,
resulting in their loss of efficacy. OMVs interact with
AMPs in a dose dependent manner and their interaction
can lead to the complete adsorption of antimicrobial
activity. In the case of bacteriophage, OMVs not only
irreversibly bind the phage, but they also greatly reduce
their ability to infect once attached to the OMV. We
further determined that OMVs production was signifi-
cantly induced in response to AMPs. While it is possible
for OMVs at sufficient concentrations to provide 100%
protection, we find that it is much more likely that vesi-
culation is a short-term response that can be upregu-
lated to neutralize low doses of stressors as a way to
“buy time” until a more persistent, adaptive resistance
mechanism is expressed. Our results are consistent with
the idea that OMV production can act as a modulated
defensive response to certain outer membrane-acting
stressors.
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Methods
Strains and cultures
E. coli strain ADA600 carrying a plasmid for kanamycin
resistance (MK496) was used in this study (WT) [9], along
with a hyper-vesiculating isogenic strain ADA600 ΔyieM
(MK1248, made by P1 phage transduction from the Keio
collection knockout strain [50]) which does not carry the
plasmid but encodes kanamycin resistance within the gene
disruption cassette. The presence of a plasmid did not
affect vesicle production or growth of ADA600 (data not
shown). ETEC was obtained from the ATCC (strain
43886, O25:K98:NM) [45]. Since ADA600 does not
encode alkaline phosphatase, MK318 (BW25113, [50]) was
used for the AP leakage assay. Vesiculation phenotypes,
responses, and antibiotic sensitivities were equivalent in
both ADA600 and BW25113 strains (data not shown).
Polymyxin B-resistant ETEC was generated by growing
ETEC in the presence of 3.5 μg/mL polymyxin B over-
night, plating the surviving culture, and growing new cul-
tures in the presence of 5 μg/mL polymyxin B. ETEC-R
was subsequently determined to be resistant to 15 μg/mL
of polymyxin B. T4 D+ bacteriophage was used in this
study. Bacterial cultures were grown in Luria-Bertani (LB)
broth (10 g/L Bactotryptone, 5 g/L yeast extract, 10 g/L
NaCl) or on LB agar plates (LB with 15 g/L BactoAgar)
supplemented with 50 μg/mL kanamycin (Sigma) or 5 μg/
mL polymyxin B (Sigma) when appropriate. Overnight
cultures (5 mL) were inoculated from individual colonies
selected from an LB agar plate. All liquid cultures were
grown using a shaking incubator (200 rpm) at 37°C.
Antimicrobials were purchased through Sigma Aldrich.
Antibiotic stocks (polymyxin B, 2.5 mg/mL; colistin 1 mg/
mL) and 10-fold dilutions of stocks were prepared fresh
the day of each experiment, stored with constant agitation
at 4°C, and used only the day they were prepared.
Survival assay
Cultures of WT and mutant E.coli were grown in LB with
kanamycin (50 μg/mL) at 37°C to an OD600 0.45. Antibio-
tics were added as indicated, treated and untreated cul-
tures were incubated further (37°C, 2 h), then a portion of
the culture plated at 10-6, 10-7, and 10-8 dilutions on LB
agar plates containing kanamycin, plates were grown for
16 h at 37°C, and colony forming units (CFU) were
counted to determine CFU/mL. For ETEC cultures, no
kanamycin was used.
OMV purification and quantitation
OMVs were prepared from overnight cultures as
described previously [9]. Briefly, cells were pelleted
(10,000 g, 15 min, 4°C) and the resulting supernatants
were filtered (0.45 μm, Millipore Durapore PVDF mem-
brane). Filtrates were centrifuged (38,400 g, 3 h, 4°C) and
the OMV containing pellets were resuspended in Dulbec-
co’s phosphate buffered saline (0.8 g KCl, 0.8 g KH2PO4,
46.8 g NaCl, 4.6 g Na2HPO4, 0.4 g MgCl2*6H2O, 0.4 g
CaCl2 in 4L dH2O) supplemented with 0.2 M NaCl
(DPBSS) and filter sterilized (0.45 μm Ultra-free spin fil-
ters, Millipore). The total protein concentration in the
purified OMV preparations was determined by Bradford
Coomassie assay (Pierce), and the OMV concentrations
used in subsequent assays refer to this protein-based
value.
To quantitate OMV yield, broth cultures were inocu-
lated at a 1:1000 dilution and grown in LB at 37°C until
the culture reached an OD600 of 0.5-0.6 at which point it
was either treated or not, as indicated, and grown over-
night (16 h) at 37°C. At the time of vesicle harvest, a por-
tion of the culture was plated on LB agar to determine
CFU/mL. OMVs were isolated as described above. Two
previously established methods, an outer membrane pro-
tein-based and lipid-based assay [9,51], were used to quan-
titate vesiculation in treated and untreated cultures. OMV
pellets were boiled in Laemmli buffer and separated by
SDS-PAGE. Gels were stained with SYPRO Ruby Red
(Molecular Probes). Bands representing OmpF/C and
OmpA were quantified by densitometry (NIH Image J
software). Lipid in the OMV pellets was measured using
the lipophilic dye FM4-64 (Invitrogen), as described pre-
viously [51]. In both cases, OMV production was normal-
ized by dividing by the CFU/mL for each culture.
Vesiculation measurements by both protein and lipid
methods were very similar, therefore only protein values
are shown. To determine relative OMV induction, OMV/
CFU values for treated cultures were divided by OMV/
CFU of an untreated culture.
OMV-mediated protection assays
Cultures of WT E. coli were grown in LB at 37°C to OD600
0.45 and treated with indicated concentrations of antibio-
tics alone, with OMVs alone (5 μg/mL), or simultaneously
with OMVs and antibiotics. Cultures were incubated (2 h,
37°C) and then plated on LB agar containing kanamycin
to determine CFUs. For ETEC experiments, indicated con-
centrations of polymyxin B, and OMVs derived from
ETEC, WT, and ETEC-R strains were used, and cultures
were plated on LB agar without kanamycin. Relative
growth (% Survival) was determined by dividing the CFUs
obtained from treated cultures by the CFUs from cultures
without antibiotic.
To titrate OMV-mediated protection, OMVs and anti-
microbials were co-incubated in 5 mL LB (2 h, 37°C) at
the indicated concentrations. The mixture was centrifuged
(38,400 g, 1 h), and the supernatant (OMV-pretreated
media) transferred to a new tube. Meanwhile, cultures of
WT or ETEC E. coli (5 mL) were grown to OD600 0.45,
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centrifuged (4100 g, 10 min), and the media was removed.
The cell pellets were then resuspended to their original
culture volume (5 mL) with OMV-pretreated media, incu-
bated (2 h, 200 rpm, 37°C), and dilution-plated on LB agar
plates (containing kanamycin for WT, not ETEC, cultures)
to determine CFU/mL. Relative growth (% Survival) was
determined by dividing the CFUs obtained from treated
cultures by the CFUs from cultures without antibiotic.
Alkaline phosphatase cell integrity assay
E. coli MK318 cultures were treated for 2 h with 0.75 μg/
mL polymyxin B, or 0.5 μg/mL colistin. A portion of the
treated and untreated cultures was dilution-plated for
CFU/mL determination. Following the treatment, cells
were pelleted (4,100 g, 10 min, 4°C), and the supernatant
was cleared of OMVs (38,400 g, 2 h, 4°C). AP was detected
in 150 μL samples of OMV-free supernatant (S) and the
whole cell pellets (WC) using the Anaspec Sensolyte
pNPP alkaline phosphatase assay kit per the manufac-
turer’s instructions. Briefly, 50 μl of sample was applied in
duplicate to each well of a 96-well plate (Corning), then
50 μl of pNPP substrate solution was added. Absorbance
at 405 nm was measured (Fluostar Optima) after 2 h. AP
concentrations in samples were derived using a standard
curve generated using known concentrations of AP. The
ratios of AP in the OMV-free supernatant compared to
the whole cells (S/WC) were then normalized to the CFU/
mL in the original cultures.
Polymyxin B resistance plate assay
To assess the time-course of the acquisition of adaptive
polymyxin B resistance, the procedure described for the
OMV protection assay was used, except that following the
indicated treatment of the ETEC cultures with ETEC
OMVs and polymyxin B, polymyxin B alone, or LB alone,
cultures were streaked on LB agar and LB agar containing
5 μg/ml of polymyxin B with a sterile applicator at 1 h
intervals for up to 7 h.
T4 titration
T4 D+ phage titering was assessed using MK496 as the
host strain. Several 10-fold dilutions of a high-concentra-
tion lysate were made, 100 μL of each of these dilutions
was then combined with 100 μL of MK496 for 5 min, the
200 μL samples were then added to warmed (55°C) top
agar (Bactotryptone 13 g/L, NaCl 8 g/L, Na-Citrate-
2H2O 2 g/L, Glucose 3 g/L, and Bactoagar 6.5 g/L) that
was diluted 1:2 with LB, and the top agar mixture was
plated on T4 plates (Bactotryptone 13 g/L, NaCl 8 g/L,
Na Citrate-2H2O 2 g/L, Glucose 1.3 g/L, and Bactoagar
10 g/L). T4 top agar and T4 plates were used for all titra-
tions and experiments using phage. Plaque forming units
(PFU) were counted by examining bacterial lawns follow-
ing overnight incubation at 37°C.
T4-OMV assays
106 T4 phage were co-incubated with 1 μg WT OMVs in
5 mL LB (2 h, 37°C). Following the incubation, 100 μL of
the solution was mixed with 100 μL of a stationary phase
culture of MK496 then mixed with 4 mL of a T4 top agar
solution (3 mL T4 top agar, 1 mL LB) and after 5 min at
25°C, plated on a T4 plate. To determine the effect of
OMVs on T4 chloroform resistance, 13 identical samples
were prepared, each containing OMVs (1 μg) and 5 mL of
LB media containing 106 T4. Chloroform (200 μL) (Mal-
linckrodt Chemical) was added to the first sample immedi-
ately upon gentle mixing, and to each of the other 12
samples at intervals every 5 min until 60 min. Following a
30 min incubation with the chloroform, at 37°C the sam-
ples were diluted and titered on MK496 to determine PFU
as described above. The PFU titer of each sample was
divided by the PFU produced by incubations with 106 T4
(% PFU Remaining).
For 60 minute incubations, MK496 cultures (5 mL) were
grown to an OD600 of 0.5-0.6, centrifuged (4100 g, 10 min,
4°C), supernatant was removed, and pellets resuspended in
the following 5 mL LB preparations using gentle pipetting:
106 T4 alone, 1 μg WT OMV alone, 105 T4 phage alone,
or 106 T4 that had been preincubated with 1 μg WT
OMV (2 h, 37°C). Cultures were allowed to grow for 1 h
at 37°C, then diluted, if necessary. A portion (200 μL) of
each sample was mixed with T4 top agar and plated as
described above. As MK496 was already present in the
samples, they did not need to be mixed with fresh cells for
titration. The PFU of each sample was divided by the PFU
resulting from the incubation with 106 T4 (% PFU
Remaining).
Electron microscopy
In advance, 400 mesh copper grids with carbon films
deposited on them (Electron Microscopy Sciences,
#CF400-cu) were cleaned via glow discharge for 1.5 min
on a Harrick Plasma Cleaner (PDC-32G). Samples were
prepared by applying 10 μL to the grid (103 T4 phage
along with 0.001 μg WT OMVs in DPBSS) and incubated
2 min, grids were then washed with 5 drops of 1% aqu-
eous uranyl acetate (Electron Microscopy Sciences). The
last drop was left to incubate on the grid for 1.5 min
before being wicked off by torn filter paper. Grids were
left to dry for 5 min before being viewed on a Tecnai 12
by FEI with a 1024 × 1024 Gatan Multi-Scan Camera
model 794.
Statistics
Error bars throughout the figures refer to standard error
for all experiments. Asterisks in figures indicate signifi-
cance as measured by Student’s T-test assuming equal
variance: *p ≤ 0.05, **p ≤ 0.001, and ***p ≤ 0.0005, n ≥
6; n values for each experiment are indicated in each
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figure legend. Each n is an independent experiment
done in at least duplicate on different days.
Additional material
Additional file 1: Figure S1. Mass spectroscopic analysis of lipid A.
Lipid A was purified as described below from MK318 (A), MK496 (B),
MK1248 (ΔyieM derivative of MK496) (C), ETEC (D), and ETEC-R (polymyxin
B resistant derivative of ETEC) (E). Samples were applied to normal phase
LC/MS and relevant areas of the spectrum are shown. Lipid A samples
were prepared as described previously [52]. Normal phase liquid
chromatography was performed on an Agilent 1200 Quaternary LC
system equipped with an Ascentis Silica HPLC column, 5 μm, 25 cm ×
2.1 mm (Sigma-Aldrich, St. Louis, MO). Mobile phase A consisted of
chloroform/methanol/aqueous ammonium hydroxide (800:195:5, v/v);
mobile phase B consisted of chloroform/methanol/water/aqueous
ammonium hydroxide (600:340:50:5, v/v); mobile phase C consisted of
chloroform/methanol/water/aqueous ammonium hydroxide (450:450:95:5,
v/v). The elution scheme for the column after loading of the sample was
as follows: 100% mobile phase A was held constant for 2 min, followed
by a linear increase to 100% mobile phase B over 14 min. The column
was then held at 100% mobile phase B for 11 min, followed by a linear
change to 100% mobile phase C over 3 min. Finally, the mobile phase
was set at 100% C for 3 min. The column was returned to 100% mobile
phase A over the course of 0.5 min and then held at 100% mobile phase
A for 5 min prior to application of the next sample. The LC flow rate was
300 μL/min. The post-column splitter diverted approximately 10% of the
LC effluent into the mass spectrometer, a QSTAR XL quadrupole time-of-
flight tandem mass spectrometer (Applied Biosystem, Foster City, CA).
Instrumental settings for negative ion electrospray (ESI) and MS/MS
analysis of lipid species were as follows: IS = -4500 V; CUR = 20 psi; GSI =
20 psi; DP = -55 V; and FP = -150 V. The MS/MS analysis used nitrogen
as the collision the gas. Each injection consisted of about 0.1% of the
total lipid extracted from a 20 mL E. coli culture, typically in 10 μL
chloroform/methanol (2:1, v/v). Data analysis was performed using
Analyst QS software (Applied Biosystem, Foster City, CA). (n = 3).
Additional file 2: Figure S2. Growth of untreated WT E. coli is
unaffected by the addition of OMVs. Relative survival (% Survival) of
antibiotic-free cultures of mid-log WT E. coli cultures supplemented with
4 μg/mL OMVs (2 h, 37°C)(Untreated +OMV) compared with non-
supplemented, antibiotic-free cultures (Untreated). (n = 9).
Additional file 3: Figure S3. Protein content in untreated and
polymyxin B-treated culture fractions are similar. Equivalent volumes
of sub-cellular fractions from untreated (A) and 0.75 μg/mL polymyxin B-
treated (2 h, 37°C) (B) log-phase cultures of MK496 were separated by
SDS-PAGE and stained using SYPRO Ruby Red. Whole cell (WC),
cytoplasm (C), inner membrane (IM), periplasm (PP), outer membrane
(OM), and OMV fractions were isolated and purified using previously
described methods [53]. The protein content and protein ratios in each
fraction are very similar for both conditions. (n = 3).
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